Saccaro coming back to Baxter as spin-off plans gain pace
This article was originally published in Clinica
James Saccaro will re-join Baxter International as chief financial officer, filling the vacancy left by current CFO Robert Hombach when he moves to the firm’s spun-out biopharmaceuticals company. The spin-out is due to complete in mid-2015. Mr Saccaro, who will report to current Baxter CEO and chair Robert Parkinson, joined the firm in 2002, reaching the position of elected corporate vice-president and treasurer in 2011. However, most recently Mr Saccaro was senior vice-president and CFO at healthcare solutions firm Hill-Rom.
You may also be interested in...
GNC hires Josh Burris as chief US officer; Clasado BioSciences adds Bellchambers as commercial director; and Barentz plans expansion with Cinven investment.
The House passage of a Democratic bill authorizing the federal government to negotiate drug prices in Medicare has sharpened the debate over how prices feed innovation, but the underlying policy stands little chance of being enacted without a Democratic wave in the next election. Pink Sheet's table highlights the key provisions of HR 3 and other pending pricing legislation.